Soleno Therapeutics Inc
6XC
Company Profile
Business description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Contact
100 Marine Parkway
Suite 400
Redwood CityCA94065
USAT: +1 650 213-8444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
152
Stocks News & Analysis
stocks
Materially undervalued ASX tech share
Long reinvestment runway supports our thesis on ASX technology company.
stocks
For US software stocks, it’s been an AI bust, not a boom
Once-hot software names are lagging. Are they good buys?
stocks
Finding value in the Aussie mining sector
Is the mining sector overvalued? A new Morningstar report highlights pockets of value that remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.20 | 19.20 | -0.22% |
| CAC 40 | 7,974.63 | 14.96 | 0.19% |
| DAX 40 | 23,258.75 | 19.57 | 0.08% |
| Dow JONES (US) | 46,448.27 | 202.86 | 0.44% |
| FTSE 100 | 9,567.43 | 32.52 | 0.34% |
| HKSE | 25,894.55 | 178.05 | 0.69% |
| NASDAQ | 22,872.01 | 598.92 | 2.69% |
| Nikkei 225 | 48,659.52 | 33.64 | 0.07% |
| NZX 50 Index | 13,480.43 | 19.42 | -0.14% |
| S&P 500 | 6,705.12 | 102.13 | 1.55% |
| S&P/ASX 200 | 8,537.00 | 26.70 | -0.31% |
| SSE Composite Index | 3,870.02 | 33.26 | 0.87% |